Lab
Action Urgent Care INC
Action Urgent Care INC was paid $44.73M by Medicaid between Jan 2018 and Aug 2024, across 31 billing codes. Its largest line is 87637, Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV — 70% of everything it billed.
33Billing provider infoACTION URGENT CARE INC
SAN JOSE, CA 95118
SAN JOSE, CA 95118
33aNPI1205186442assigned 09/14/2012
33bProvider typeClinical Medical Laboratory
28Total paid$44.73M
24GClaims622,004
24DCodes billed31
24AFirst – last monthJan 2018 – Aug 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#23 of 561
Median peer was paid$222K
This provider vs. median202×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16 | $939.04 | |
| 2020 | 2,337 | $37K | |
| 2021 | 4,463 | $80K | |
| 2022 | 130,250 | $5.33M | |
| 2023 | 356,730 | $31.01M | |
| 2024incomplete | 128,208 | $8.27M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 70% | 240,015 | 105,990 | $31.42M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 13% | 216,515 | 104,044 | $5.94M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 7.5% | 47,821 | 30,585 | $3.37M |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 5.1% | 45,044 | 44,602 | $2.28M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 24,826 | 15,357 | $733K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 18,027 | 13,584 | $357K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,007 | 1,222 | $112K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,621 | 1,317 | $111K |
| 87634 | <1% | 2,010 | 1,222 | $93K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 4,507 | 4,168 | $80K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 2,477 | 2,450 | $69K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,509 | 1,972 | $41K |
19 more codes
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,103 | $38K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 2,444 | $37K |
| 87428 | <1% | 984 | $32K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 374 | $2K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 68 | $1K |
| 87430 | <1% | 696 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 97 | $364.01 |
| 81003 | <1% | 275 | $197.37 | |
| 99051 | <1% | 5,053 | $173.00 | |
| 87400 | <1% | 84 | $161.65 | |
| 81025 | <1% | 78 | $145.10 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 72 | $143.02 |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 15 | $96.00 |
| 99072 | <1% | 65 | $90.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 23 | $46.80 |
| 99401 | <1% | 12 | $32.01 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 36 | $0.56 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 17 | $0.00 |
| 99050 | 0% | 129 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSKOROKHOD, VLADIMIR (CEO)